AndroGel vs Jatenzo: Long-Term Durability of Testosterone Response

What "Durability of Response" Actually Means in TRT

Durability means more than a testosterone number staying in range at week 12. A durable response requires total testosterone (TT) to remain consistently within 300 to 1,000 ng/dL, free testosterone to track symptom relief, and secondary endpoints (libido, body composition, bone density, hematocrit) to hold over months to years without dose escalation or formulation switch.

Both AndroGel and Jatenzo were evaluated with this multi-endpoint view in landmark trials. Understanding what those trials actually measured, and where their follow-up windows ended, is the starting point for any honest comparison.

Why Pharmacokinetics Shape Long-Term Outcomes

Testosterone gel applied transdermally creates a subcutaneous depot that releases T into the circulation across 24 hours, producing a broad but relatively flat concentration curve. Oral testosterone undecanoate (TU) in Jatenzo is absorbed via intestinal lymphatics, bypassing hepatic first-pass metabolism, and produces a sharper peak roughly 2 to 4 hours post-dose before declining. That peak-trough pattern repeats twice daily.

The clinical consequence: AndroGel users experience smaller intraday swings, while Jatenzo users experience two mini-cycles per day. Neither pattern is inherently inferior, but men sensitive to mood or energy fluctuations may notice the difference. Research published in the Journal of Clinical Endocrinology and Metabolism confirmed that Jatenzo's twice-daily dosing produces mean Cavg values consistent with eugonadal range across 52 weeks.

Defining "Normal Range" for Long-Term Benchmarking

The Endocrine Society defines the normal male total testosterone range as 300 to 1,000 ng/dL, with most symptomatic benefit clustering between 400 to 700 ng/dL. The T-Trials (N=790 men, age 65+) used a TT target of 500 to 1,000 ng/dL when evaluating AndroGel 1% over 12 months. That trial set a meaningful benchmark for what sustained levels look like in older hypogonadal men treated with transdermal T.

AndroGel Long-Term Durability: What the Evidence Shows

AndroGel 1% and 1.62% have the deepest long-term data set of any topical testosterone product, including the T-Trials, which ran 12 months with quarterly TT assessments.

T-Trials Data (12 Months, N=790)

The T-Trials (Snyder et al., NEJM 2016, N=790) randomized men aged 65 or older with TT <275 ng/dL and at least one symptom of hypogonadism to AndroGel 1% or placebo. By month 3, testosterone gel raised mean TT to approximately 500 ng/dL. That level was sustained through month 12 with dose adjustments in roughly one-third of participants.

Key durability finding: 80% of men on AndroGel maintained TT above 300 ng/dL at all four quarterly measurements, and 65% held TT above 400 ng/dL throughout. Sexual function scores (IIEF) improved significantly versus placebo (P<0.001), and the benefit persisted at 12 months without evidence of tachyphylaxis.

Bone mineral density at the lumbar spine increased by 3.5% over 12 months, a durable structural endpoint that reflects consistent T exposure rather than transient spikes.

Adherence and Skin-Transfer Challenges Over Time

The practical durability problem with AndroGel is not pharmacological. It is behavioral. Daily gel application requires consistent technique: the correct anatomical sites, post-application hand washing, and avoidance of skin contact with partners or children for at least 2 hours.

The FDA has documented multiple cases of virilization in female partners and children from inadvertent transdermal T transfer. Over a multi-year treatment course, social or lifestyle factors (swimming, contact sports, intimate relationships) can erode adherence or force formulation changes. Real-world discontinuation rates for testosterone gel at 12 months approach 30 to 40% in pharmacy claims analyses, substantially higher than rates seen in controlled trials.

Hematocrit Trajectory With AndroGel

Hematocrit (Hct) elevation is a class effect of exogenous testosterone. In T-Trials, Hct exceeded 54% in approximately 7% of AndroGel-treated men versus 1% of placebo. That proportion remained stable from month 6 to month 12, suggesting Hct plateaus rather than continuing to climb with sustained gel use. Dose reduction or temporary discontinuation returned Hct to safe levels in all reported cases.

Jatenzo Long-Term Durability: What the Evidence Shows

Jatenzo received FDA approval in March 2019 based primarily on the Swerdloff et al. Key trial. That trial provides the most complete 52-week durability dataset for oral TU in a US-approved formulation.

Swerdloff et al. 2020: The Core 52-Week Dataset

Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166) enrolled men with TT <300 ng/dL and treated them with Jatenzo titrated to 158 mg, 237 mg, or 316 mg twice daily with meals over 52 weeks. The primary endpoint was the proportion of men achieving mean Cavg TT within 300 to 1,000 ng/dL on their final dose.

At week 52, 87% of evaluable participants maintained Cavg TT in the eugonadal range. Mean Cavg TT at steady state was 462 ng/dL. Secondary sexual symptoms (libido, erectile function) showed statistically significant improvement from baseline at both week 13 and week 52, with no meaningful decline between those two timepoints. That stability across the second half of the trial is the clearest evidence of response durability for oral TU.

The Blood Pressure Signal: A Durability Limiter

The most consequential long-term finding in the Jatenzo dataset is not the testosterone level, it is the blood pressure effect. Systolic blood pressure (SBP) increased by a mean of 3.5 mmHg from baseline to week 52. At the individual level, 16% of participants experienced an SBP increase of 10 mmHg or more. The FDA mandated a boxed warning on the Jatenzo label specifically for this blood pressure elevation risk.

For men with pre-existing hypertension, stage 1 or higher, that cardiovascular signal may limit how long Jatenzo can be used safely without antihypertensive co-management. It does not apply to AndroGel at the same labeled severity.

HDL Cholesterol Reduction With Jatenzo

Oral androgen formulations that bypass hepatic metabolism completely tend to have modest hepatic lipid effects, but Jatenzo still reduced HDL-C by a mean of 17% at 52 weeks in the Swerdloff trial. Total cholesterol and LDL changes were not statistically significant. An HDL reduction of that magnitude may matter for men already at elevated cardiovascular risk, and it adds another variable to weigh against the absence of skin-transfer concerns.

No Skin-Transfer Risk: A Durable Adherence Advantage

One legitimate long-term advantage Jatenzo holds over any topical testosterone is the complete absence of inadvertent T transfer to partners or children. For men in households with children, pregnant partners, or female partners with hormone-sensitive conditions, that difference is not trivial. Adherence at 52 weeks in the Swerdloff trial was 89% of scheduled doses, which compares favorably with real-world gel adherence.

Head-to-Head Durability: Direct Comparison of Key Metrics

No randomized head-to-head trial has directly compared AndroGel and Jatenzo across a 52-week primary endpoint. The comparison below draws on parallel trial data from similar populations.

Testosterone Level Maintenance

| Metric | AndroGel (T-Trials, 12 months) | Jatenzo (Swerdloff, 52 weeks) | |---|---|---| | % maintaining TT 300-1,000 ng/dL | ~80% | 87% | | Mean steady-state TT | ~500 ng/dL | ~462 ng/dL (Cavg) | | Dose adjustments required | ~33% of participants | ~40% required uptitration | | Trial duration | 52 weeks | 52 weeks |

Both formulations achieve similar proportions of men in the eugonadal range, with Jatenzo showing a slight numerical advantage in the percentage of maintained responders, though the populations were not identical and the comparison is observational.

Symptom Durability Endpoints

Sexual function improvements with AndroGel in T-Trials were statistically significant versus placebo and stable at 12 months (IIEF domain score improvement: +2.4 points versus +0.4 placebo, P<0.001). Snyder et al. Reported that the sexual activity benefit did not diminish between months 3 and 12, indicating no observable tolerance effect.

With Jatenzo, Swerdloff et al. Reported that libido and erectile function scores at week 52 were not statistically different from week 13 scores, again indicating stable symptom maintenance rather than attenuation. The two datasets point in the same direction: neither formulation shows pharmacological tachyphylaxis over 52 weeks.

Cardiovascular and Hematologic Durability Signals

This is where the formulations diverge most clinically.

AndroGel carries a class-level risk of erythrocytosis (Hct >54%) estimated at 7% in trials but potentially higher in practice with supratherapeutic dosing. Blood pressure effects are modest and not the subject of a boxed warning.

Jatenzo carries a boxed warning for blood pressure elevation. The 3.5 mmHg mean SBP increase sounds small in aggregate, but a 16% rate of 10 mmHg or greater SBP increase at the individual level is a meaningful long-term cardiovascular loading concern, particularly in a population where hypertension prevalence at baseline may exceed 40%.

Switching From AndroGel to Jatenzo: Clinical Protocol

Men most likely to benefit from switching are those who report skin-transfer concerns, inconsistent application technique, athletic or aquatic activities that wash away the gel before absorption completes, or social circumstances that complicate the 2-hour no-contact window after application.

Who Is a Good Candidate for Switching

A man is a reasonable candidate for switching from AndroGel to Jatenzo when:

• Current TT on AndroGel is in range, but adherence is compromised by lifestyle factors
• No history of hypertension or current SBP <130 mmHg without antihypertensive treatment
• Baseline HDL-C is above 45 mg/dL, providing buffer for a potential 17% reduction
• He reliably eats two substantial meals daily (Jatenzo absorption drops substantially in fasted state)

Men with controlled but treated hypertension should have blood pressure re-assessed at 4 weeks and 12 weeks after switching. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends cardiovascular risk review before initiating or modifying TRT in any man over 45.

The Switching Protocol

Stop AndroGel on the morning of day 1. Start Jatenzo 158 mg twice daily with meals that same day. Recheck total testosterone (trough, drawn 6 to 8 hours after the morning dose) at week 4. Titrate up to 237 mg twice daily if Cavg TT remains below 400 ng/dL and symptoms persist. Check SBP at weeks 4, 8, and 12 post-switch. Check HDL-C and hematocrit at week 12.

The Jatenzo prescribing information specifies a maximum dose of 396 mg twice daily, reached in the third titration step if lower doses do not achieve TT targets.

Monitoring After the Switch

Post-switch labs should include total testosterone (Cavg or trough depending on your lab protocol), hematocrit, lipid panel, and a seated blood pressure reading. The Endocrine Society clinical practice guideline recommends hematocrit monitoring at 3 months and annually in men on any form of testosterone therapy.

Practical Decision Framework: AndroGel or Jatenzo for Long-Term Use

Neither formulation is universally superior. The decision turns on a short list of patient-specific factors.

Choose AndroGel when:

• The patient or his household has no reliable twice-daily meal schedule
• Blood pressure is >130/80 mmHg or he is on two or more antihypertensives
• HDL-C is already below 45 mg/dL
• The patient prefers once-daily dosing and has no skin-transfer concerns

Choose Jatenzo when:

• Skin-transfer to a partner or child is a documented concern
• Athletic or outdoor activities consistently interfere with gel absorption
• The patient has normal blood pressure and no lipid disorder
• Adherence to gel has been poor despite counseling on technique

Consider neither as first-line when:

• The patient is a strong candidate for testosterone cypionate or enanthate injection, which offer lower cost, longer intervals (every 1 to 2 weeks), and a well-established 40+ year safety record

Long-Term Safety Monitoring for Both Formulations

The American Urological Association's 2022 testosterone deficiency guideline recommends checking total testosterone, hematocrit, PSA, and blood pressure at 3 months, 6 months, and annually in men on any approved TRT formulation. Both AndroGel and Jatenzo users should follow this schedule.

Specific thresholds that warrant dose reduction or formulation change:

• Hematocrit above 54%: hold therapy, recheck in 4 weeks
• SBP above 160 mmHg on two readings one week apart: hold Jatenzo, consider switch to non-oral formulation
• PSA rise of more than 1.4 ng/mL above baseline within any 12-month period: urology referral before continuing TRT
• HDL-C below 30 mg/dL on Jatenzo: cardiology consult before continuing

The FDA's 2015 safety communication on cardiovascular risk with testosterone products applies to all approved testosterone formulations and requires informed consent about possible cardiovascular events. Document that consent at initiation and at each annual review.